| Nov 1 |
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst
|
| Oct 31 |
Vanda started at buy by H.C. Wainwright, negative enterprise value cited
|
| Oct 31 |
Health Care Roundup: Market Talk
|
| Oct 30 |
Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024
|
| Oct 17 |
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
|
| Oct 15 |
VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises
|
| Oct 15 |
Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals
|
| Oct 14 |
Vanda Pharma soars as Cycle Pharma reiterates $8/share offer (update)
|
| Oct 14 |
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.
|
| Oct 14 |
Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer
|
